Pub Date : 2023-12-31DOI: 10.23937/2377-3634/1410173
Caudell Chloe W, Wilson Jon D, Sessions William S
Background: Weight gain is linked to poor glycemic control in Type 2 Diabetes patients especially in resource restrained environment, and it is made worse by the lack of access to sustainable treatment options in these same environments. Due to poverty and limited financial resources, these individuals must prioritize safer, locally accessible
{"title":"In a Changing World of Disease Prevalence, We Must Change Our Differentials: A Case of Diabetic Myonecrosis","authors":"Caudell Chloe W, Wilson Jon D, Sessions William S","doi":"10.23937/2377-3634/1410173","DOIUrl":"https://doi.org/10.23937/2377-3634/1410173","url":null,"abstract":"Background: Weight gain is linked to poor glycemic control in Type 2 Diabetes patients especially in resource restrained environment, and it is made worse by the lack of access to sustainable treatment options in these same environments. Due to poverty and limited financial resources, these individuals must prioritize safer, locally accessible","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":"115 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139135278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-31DOI: 10.23937/2377-3634/1410174
Alam Md Ejaz, Bhat Mohammad Hayat Ahmad, Patto Shoiab M, Bhat Mohammad Afaan
{"title":"Insulin Injection Abscesses caused by Bacteria of the Burkholderia cepacia Complex","authors":"Alam Md Ejaz, Bhat Mohammad Hayat Ahmad, Patto Shoiab M, Bhat Mohammad Afaan","doi":"10.23937/2377-3634/1410174","DOIUrl":"https://doi.org/10.23937/2377-3634/1410174","url":null,"abstract":"","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":"73 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139130378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-31DOI: 10.23937/2377-3634/1410172
Akoko Sokiprim, Siminialayi Iyeopu M, Chinenye Sunday
{"title":"Glycaemic Control and Weight Reduction in Type 2 Diabetes Mellitus Patient Using a Wholly Nigerian Diet - A Hospital Based Study","authors":"Akoko Sokiprim, Siminialayi Iyeopu M, Chinenye Sunday","doi":"10.23937/2377-3634/1410172","DOIUrl":"https://doi.org/10.23937/2377-3634/1410172","url":null,"abstract":"","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":"101 29","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139133789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2377-3634/1410167
Panigrahi Gunadhar
Background: Type 2 Diabetes (T2D) is a chronic progressive disease, and its prevalence is on the rise around the world. Despite advances in pharmacotherapy, mitigating the burden of the disease on individuals, societies and the healthcare system remains a challenge. Remission has emerged as a therapeutic target in T2D with wide range of interventions. A plant-based diet seems to be promising to achieve
{"title":"Remission of Type 2 Diabetes with High-Fiber, Low-Fat, and Calorie Restricted Plant-Based Diet Study","authors":"Panigrahi Gunadhar","doi":"10.23937/2377-3634/1410167","DOIUrl":"https://doi.org/10.23937/2377-3634/1410167","url":null,"abstract":"Background: Type 2 Diabetes (T2D) is a chronic progressive disease, and its prevalence is on the rise around the world. Despite advances in pharmacotherapy, mitigating the burden of the disease on individuals, societies and the healthcare system remains a challenge. Remission has emerged as a therapeutic target in T2D with wide range of interventions. A plant-based diet seems to be promising to achieve","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48763430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2377-3634/1410171
Issah Shani, Harrison Obed Akwaa, Danquah Angelina O, Mumuni Kamal Sumani, Salifu Iddrisu, A. Mutala, Aseidu Matilda Steiner
Background and Objectives: Glucose imbalance or impaired fasting glycemia refers to a condition where there is imbalance in blood sugar levels in an individual. This is usually influenced by the inability of the kidneys to properly convert excess sugar into a form that can easily be eliminated from the body. Accumulation of excess sugar in the body leads to the occurrence of Type 2 diabetes mellitus
{"title":"Determinants of Glucose Imbalance and its Effects on Developing Undiagnosed Type 2 Diabetes Mellitus in an Urban and Rural Ghanaian Community","authors":"Issah Shani, Harrison Obed Akwaa, Danquah Angelina O, Mumuni Kamal Sumani, Salifu Iddrisu, A. Mutala, Aseidu Matilda Steiner","doi":"10.23937/2377-3634/1410171","DOIUrl":"https://doi.org/10.23937/2377-3634/1410171","url":null,"abstract":"Background and Objectives: Glucose imbalance or impaired fasting glycemia refers to a condition where there is imbalance in blood sugar levels in an individual. This is usually influenced by the inability of the kidneys to properly convert excess sugar into a form that can easily be eliminated from the body. Accumulation of excess sugar in the body leads to the occurrence of Type 2 diabetes mellitus","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45543098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2377-3634/1410170
Haase Christie
Background: One in ten adults in the United States has diabetes; the vast majority are diagnosed with type two diabetes mellitus (T2DM). Even though diabetes care has significantly evolved, and a wide variety of pharmacological treatments are available, approximately one-half of people with type two diabetes do not achieve a hemoglobin A1C of less than seven percent. In addition, self-management is a consequential contributor to glycemic control. In light of the mortality, morbidity, decreased quality of life, and financial burden caused by T2DM, the author wanted to explore the diagnosis experiences of type two diabetics. Could their experiences be a contributing factor to less-than-optimal treatment outcomes? Methods: The author interviewed nine consenting adults with T2DM in person, over the telephone, and via videoconference over four weeks in March and April 2023. The data from each transcript was analyzed independently and then compared, identifying meanings and clustering themes found throughout utilizing descriptive phenomenology as the underpinning for this study.
{"title":"Back to the Beginning: Diagnosis Experiences of Persons with Type Two Diabetes","authors":"Haase Christie","doi":"10.23937/2377-3634/1410170","DOIUrl":"https://doi.org/10.23937/2377-3634/1410170","url":null,"abstract":"Background: One in ten adults in the United States has diabetes; the vast majority are diagnosed with type two diabetes mellitus (T2DM). Even though diabetes care has significantly evolved, and a wide variety of pharmacological treatments are available, approximately one-half of people with type two diabetes do not achieve a hemoglobin A1C of less than seven percent. In addition, self-management is a consequential contributor to glycemic control. In light of the mortality, morbidity, decreased quality of life, and financial burden caused by T2DM, the author wanted to explore the diagnosis experiences of type two diabetics. Could their experiences be a contributing factor to less-than-optimal treatment outcomes? Methods: The author interviewed nine consenting adults with T2DM in person, over the telephone, and via videoconference over four weeks in March and April 2023. The data from each transcript was analyzed independently and then compared, identifying meanings and clustering themes found throughout utilizing descriptive phenomenology as the underpinning for this study.","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49118754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Diabetic retinopathy is a complication of type 2 diabetes resulting from long-term accumulated damage to retinal blood vessels and one of the life-threatening complications and is the most common cause of acquired blindness in adults and it affects 93 million people worldwide. DR is the principal cause of blindness in adults of working age and responsible for a worsening in quality of life despite preventable and treatable causes. To date, most of the epidemiological research on DR in Ethiopia has been limited to prevalence estimates from cross-sectional studies. This study determined the incidence of retinopathy and its predictors among type 2 diabetic patients Methods: Hospital-based retrospective follow-up study was conducted among 420 adults with newly diagnosed type 2 diabetic patients from January 1, 2014, to December 31, 2019. Data were extracted from medical records and entered into Epi info version7.2.2.6and exported to Stata 14 for analysis. Bivariable and multivariable Cox proportional hazard model were used to identify predictors of diabetic retinopathy. In a multivariable analysis variable having a p-value < 0.05 in the Cox; PH model was considered as predictors of diabetic retinopathy. Results: Overall, 19.5% (95% CI; 16.2-23.8) of the study population developed diabetic retinopathy, with a median survival time of 30.4 months. Congestive heart failure [AHR: 2.53 (95% CI; 1.49, 4.29)], chronic kidney disease [AHR: 5.02(95% CI; 2.73, 9.26)], hypertension [AHR: 2.07(95% CI; 1.17, 2.89)], and HBA1c [AHR: 10.5 (95% CI; 5.6, 19.6)] were found to be predictors of diabetic retinopathy.
{"title":"Incidence and Predictors of Diabetic Retinopathy among Newly Diagnosed Type 2 Diabetic Patients at Chronic Follow-Up Clinic of University of Gondar Specialized Hospital: A Retrospective Follow-Up Study","authors":"Tassew Worku Chekol, Birhan Nigussie, Zewdu Yemataw","doi":"10.23937/2377-3634/1410169","DOIUrl":"https://doi.org/10.23937/2377-3634/1410169","url":null,"abstract":"Background: Diabetic retinopathy is a complication of type 2 diabetes resulting from long-term accumulated damage to retinal blood vessels and one of the life-threatening complications and is the most common cause of acquired blindness in adults and it affects 93 million people worldwide. DR is the principal cause of blindness in adults of working age and responsible for a worsening in quality of life despite preventable and treatable causes. To date, most of the epidemiological research on DR in Ethiopia has been limited to prevalence estimates from cross-sectional studies. This study determined the incidence of retinopathy and its predictors among type 2 diabetic patients Methods: Hospital-based retrospective follow-up study was conducted among 420 adults with newly diagnosed type 2 diabetic patients from January 1, 2014, to December 31, 2019. Data were extracted from medical records and entered into Epi info version7.2.2.6and exported to Stata 14 for analysis. Bivariable and multivariable Cox proportional hazard model were used to identify predictors of diabetic retinopathy. In a multivariable analysis variable having a p-value < 0.05 in the Cox; PH model was considered as predictors of diabetic retinopathy. Results: Overall, 19.5% (95% CI; 16.2-23.8) of the study population developed diabetic retinopathy, with a median survival time of 30.4 months. Congestive heart failure [AHR: 2.53 (95% CI; 1.49, 4.29)], chronic kidney disease [AHR: 5.02(95% CI; 2.73, 9.26)], hypertension [AHR: 2.07(95% CI; 1.17, 2.89)], and HBA1c [AHR: 10.5 (95% CI; 5.6, 19.6)] were found to be predictors of diabetic retinopathy.","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41317562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2377-3634/1410168
Singh Yudhyavir, S. Abhishek, Surbhi Surbhi, Soni Kapil Dev, Aggarwal Richa, Trikha Anjan
Background: The blood glucose level in a patient with diabetes is an important prognostic factor for any form of severe illness requiring intensive care hospitalization. We conducted this retrospective study to examine the effect of hyperglycemia on outcomes in patients with diabetes with coronavirus diseases (COVID-19) admitted to the intensive care unit (ICU). Method: A retrospective analysis of 25 adult patients with diabetes with COVID-19 admitted to the ICU between 1st January to 15 th February 2021 was done. Demographics details, past medical history, random blood sugar, medical management, ventilatory requirements, and survival data were obtained from medical record files and computerized patient recording systems. Outcomes such as mortality, need for mechanical ventilation, length of ICU stay, and length of hospital stay were analyzed. Result: The median age of the patients was 61 years with a male preponderance. Hypertension is the most common co-morbidity associated with diabetes patients. The median blood sugar level was consistently high in the non-survivors although the result was not statistically significant. Clinical management showed that 84% of patients received insulin, 16% (oral hypoglycemic agents) 72% (steroids) and (64%) mechanical ventilation. The median ICU stay was 8(2-72) days, the median hospital stay was 13(6-79) days and overall mortality in patients with diabetes with COVID-19 was 52%. Conclusion: Hyperglycemia in critically ill COVID-19 patients with preexisting diabetes shows worst outcome in terms of complications, need for mechanical ventilation, and mortality a well-designed prospective study is needed to determine the optimal target for glucose control and its effect on outcomes in patients with diabetes and COVID-19.
{"title":"The Effect of Hyperglycemia on Outcome in COVID-19 Patients with Known Diabetes: A Retrospective Observational Study","authors":"Singh Yudhyavir, S. Abhishek, Surbhi Surbhi, Soni Kapil Dev, Aggarwal Richa, Trikha Anjan","doi":"10.23937/2377-3634/1410168","DOIUrl":"https://doi.org/10.23937/2377-3634/1410168","url":null,"abstract":"Background: The blood glucose level in a patient with diabetes is an important prognostic factor for any form of severe illness requiring intensive care hospitalization. We conducted this retrospective study to examine the effect of hyperglycemia on outcomes in patients with diabetes with coronavirus diseases (COVID-19) admitted to the intensive care unit (ICU). Method: A retrospective analysis of 25 adult patients with diabetes with COVID-19 admitted to the ICU between 1st January to 15 th February 2021 was done. Demographics details, past medical history, random blood sugar, medical management, ventilatory requirements, and survival data were obtained from medical record files and computerized patient recording systems. Outcomes such as mortality, need for mechanical ventilation, length of ICU stay, and length of hospital stay were analyzed. Result: The median age of the patients was 61 years with a male preponderance. Hypertension is the most common co-morbidity associated with diabetes patients. The median blood sugar level was consistently high in the non-survivors although the result was not statistically significant. Clinical management showed that 84% of patients received insulin, 16% (oral hypoglycemic agents) 72% (steroids) and (64%) mechanical ventilation. The median ICU stay was 8(2-72) days, the median hospital stay was 13(6-79) days and overall mortality in patients with diabetes with COVID-19 was 52%. Conclusion: Hyperglycemia in critically ill COVID-19 patients with preexisting diabetes shows worst outcome in terms of complications, need for mechanical ventilation, and mortality a well-designed prospective study is needed to determine the optimal target for glucose control and its effect on outcomes in patients with diabetes and COVID-19.","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48843004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Pediatric and youth diabetes mellitus (DM) and pediatric and youth human immunodeficiency virus (HIV) infection are among the chronic diseases with significant public health implications and high mortality. The availability of mortality statistics in type 1 diabetes and HIV/AIDS is critical for addressing the two conditions in one setting. Objective: To compare the mortality of children and youth living with Diabetes (CYLDM) versus children and youth living with HIV (CYLHIV). Methods: This retrospective cross-sectional approach extracted data from registries of Tanzania Diabetes Association (TDA) and National AIDS Control Programme (NACP). Mortality was defined as death recorded in the registry. STATA version 14 was used for analysis. Results: A total of 3822 data for CYLDM and 33,941 CYLHIV were extracted. Almost fifty-one per cent (50.8%) and 27.2% were males CYLDM and CYLHIV respectively, mean age (SD) at diagnosis was 14 (± 5.8) and 9.4 (± 7.3) years for CYLDM and CYLHIV, respectively. Total death was 95 (3.0%) in CYLDM and 3718 (11%) in CYLHIV. Mean age (SD) at death was 17 (± 4.5) years for CYLDM and 11 (± 8) years for CYLHIV. The loss to follow up rate was 33.7% for CYLDM and 43.7% for CYLHIV. Conclusion: The estimated death rate was high in CYLHIV compared to CYLDM. Both conditions had a high rate of loss to follow up. This study serves as the basis for prospective studies to determine causes and possible mitigation against mortality and loss to follow up in these two chronic conditions.
{"title":"High Rate of Mortality in Children and Youth with HIV Infection Compared to those with Diabetes in Tanzania","authors":"Majaliwa Edna S, Ndayongeje Joel, Ramaiya Kaushik, Mmbaga Blandina T, Mfinanga Sayoki G","doi":"10.23937/2377-3634/1410166","DOIUrl":"https://doi.org/10.23937/2377-3634/1410166","url":null,"abstract":"Background: Pediatric and youth diabetes mellitus (DM) and pediatric and youth human immunodeficiency virus (HIV) infection are among the chronic diseases with significant public health implications and high mortality. The availability of mortality statistics in type 1 diabetes and HIV/AIDS is critical for addressing the two conditions in one setting. Objective: To compare the mortality of children and youth living with Diabetes (CYLDM) versus children and youth living with HIV (CYLHIV). Methods: This retrospective cross-sectional approach extracted data from registries of Tanzania Diabetes Association (TDA) and National AIDS Control Programme (NACP). Mortality was defined as death recorded in the registry. STATA version 14 was used for analysis. Results: A total of 3822 data for CYLDM and 33,941 CYLHIV were extracted. Almost fifty-one per cent (50.8%) and 27.2% were males CYLDM and CYLHIV respectively, mean age (SD) at diagnosis was 14 (± 5.8) and 9.4 (± 7.3) years for CYLDM and CYLHIV, respectively. Total death was 95 (3.0%) in CYLDM and 3718 (11%) in CYLHIV. Mean age (SD) at death was 17 (± 4.5) years for CYLDM and 11 (± 8) years for CYLHIV. The loss to follow up rate was 33.7% for CYLDM and 43.7% for CYLHIV. Conclusion: The estimated death rate was high in CYLHIV compared to CYLDM. Both conditions had a high rate of loss to follow up. This study serves as the basis for prospective studies to determine causes and possible mitigation against mortality and loss to follow up in these two chronic conditions.","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48351228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31DOI: 10.23937/2377-3634/1410165
Minh Le A, Tu Do A, A. Khaiat
Diabetes mellitus is a serious global concern due to its long-term health-related effects and the financial burden it poses to healthcare systems and families around the world. Excess consumption of sugar is one of the main causes of the issue. There are many sweetening ingredients that claim to be the solution to substitute normal sugar while maintaining the blood sugar level at a low level, yet the evidence is lacking and not always substantiated. Sweetch Natural Sugar Replacement is a proprietary natural sugar alternative product composed of a blend of different plant-derived sweetening ingredients. It has zero calories, no added flavor, non-GMO, and the same taste profile and measure as sugar (1:1 replacement). It is appropriate in drinks as well as any form of cooking. The objective of this study is to evaluate changes in blood sugar levels, as well as the safety of human volunteers after oral absorption of Sweetch Natural Sugar Replacement, substantiating Sweetch claim on zero glycemic response. The efficacy and safety analyses were performed using the principles of a fasting blood sugar level test on 22 randomized subjects practicing a healthy lifestyle. Participants were divided into 2 groups: An active group using the investigational product (IP; 50 g of the IP dissolved into mineral water.) versus a controlled group using a placebo (plain mineral water). After 12 hours of overnight fasting, volunteers took their drink orally and their blood samples were taken at specific time points (T0, T30 min, and T2 h) to measure blood glucose levels. Results indicate that there is no significant difference in the average blood glucose level at various time points between the active group and the placebo group. This study confirms that Sweetch Natural Sugar Replacement does not cause any noticeable changes in blood sugar levels post-oral administration. No adverse health events were observed throughout the study. Through this study, Sweetch Natural Sugar Replacement’s claim on zero glycemic index (GI) is proven legitimate.
{"title":"A Randomized, Double-Blind, Monocentric, and Placebo-Controlled Blood Glycemic Response Evaluation of Sweetch, a Natural Sugar Replacement Blend, on Healthy Volunteers","authors":"Minh Le A, Tu Do A, A. Khaiat","doi":"10.23937/2377-3634/1410165","DOIUrl":"https://doi.org/10.23937/2377-3634/1410165","url":null,"abstract":"Diabetes mellitus is a serious global concern due to its long-term health-related effects and the financial burden it poses to healthcare systems and families around the world. Excess consumption of sugar is one of the main causes of the issue. There are many sweetening ingredients that claim to be the solution to substitute normal sugar while maintaining the blood sugar level at a low level, yet the evidence is lacking and not always substantiated. Sweetch Natural Sugar Replacement is a proprietary natural sugar alternative product composed of a blend of different plant-derived sweetening ingredients. It has zero calories, no added flavor, non-GMO, and the same taste profile and measure as sugar (1:1 replacement). It is appropriate in drinks as well as any form of cooking. The objective of this study is to evaluate changes in blood sugar levels, as well as the safety of human volunteers after oral absorption of Sweetch Natural Sugar Replacement, substantiating Sweetch claim on zero glycemic response. The efficacy and safety analyses were performed using the principles of a fasting blood sugar level test on 22 randomized subjects practicing a healthy lifestyle. Participants were divided into 2 groups: An active group using the investigational product (IP; 50 g of the IP dissolved into mineral water.) versus a controlled group using a placebo (plain mineral water). After 12 hours of overnight fasting, volunteers took their drink orally and their blood samples were taken at specific time points (T0, T30 min, and T2 h) to measure blood glucose levels. Results indicate that there is no significant difference in the average blood glucose level at various time points between the active group and the placebo group. This study confirms that Sweetch Natural Sugar Replacement does not cause any noticeable changes in blood sugar levels post-oral administration. No adverse health events were observed throughout the study. Through this study, Sweetch Natural Sugar Replacement’s claim on zero glycemic index (GI) is proven legitimate.","PeriodicalId":92797,"journal":{"name":"International journal of diabetes and clinical research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48493990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：